Cita APA (7a ed.)

Peng, D. H., Rodriguez, B. L., Diao, L., Gaudreau, P., Padhye, A., Konen, J. M., . . . Gibbons, D. L. (2021). Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers. Nature Portfolio.

Cita Chicago Style (17a ed.)

Peng, David H., et al. Th17 Cells Contribute to Combination MEK Inhibitor and Anti-PD-L1 Therapy Resistance in KRAS/p53 Mutant Lung Cancers. Nature Portfolio, 2021.

Cita MLA (8a ed.)

Peng, David H., et al. Th17 Cells Contribute to Combination MEK Inhibitor and Anti-PD-L1 Therapy Resistance in KRAS/p53 Mutant Lung Cancers. Nature Portfolio, 2021.